Depomed Will Cease All Spending on Sefelsa

Depomed, Inc. (Nasdaq: DEPO ), a specialty pharmaceutical company, announced today that the Reproductive Health Drugs Advisory Committee (RHDAC) of the U.S. Food and Drug Administration (FDA) voted 2-12 against approval for SEFELSA, Depomed's investigational, oral, twice daily formulation of gabapentin,^ to treat moderate to severe vasomotor symptoms due to menopause. SEFELSA is the proposed